相关实验视频

Updated: May 30, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

案例报告:在三阴性乳腺癌中,通过无环素治疗方案治疗的病理完整反应

Francesca Piazza¹, Giulia Scartabellati¹, Laura Moretti¹

¹Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia, Azienda socio-sanitaria territoriale (ASST) Spedali Civili, Brescia, Italy.

Frontiers in oncology

|February 16, 2026

概括

一名患有高风险的三阴性乳腺癌的患者在不使用 antracyclines 的情况下实现了病理完整反应. 这一案例表明,降级化疗免疫疗法可能是可行的,但需要进一步的研究来选择患者.

科学领域:

在瘤学瘤学.
乳腺癌研究研究乳腺癌研究
临床案例研究临床案例研究

背景情况:

三阴性乳腺癌 (TNBC) 是具有不良结果的侵略性.
新辅助化疗免疫疗法 (KEYNOTE-522) 是一种标准的护理,改善了病理完整反应 (pCR) 和存活率.
治疗降级,省略人环素,正在探索以减少毒性,但缺乏临床验证.

研究的目的:

在高风险的TNBC中报告成功的新辅助化疗-免疫疗法的临床案例,而没有人环素.
探索在选择的TNBC患者中减缓治疗升级的可能性.
讨论患者选择和预测生物标志物对新辅助疗法反应的挑战.

主要方法:

一名患有cT4a cN0 TNBC的54岁女性接受了新辅助药布罗利祖马布加化疗.
由于epirubicin扩散,治疗方法被修改,省略了进一步的Anthracyclines.
患者接受了手术,并评估了病理完整反应 (pCR).

主要成果:

尽管遗漏了环素,但患者实现了pCR (ypT0,ypN0).
放射性评估显示,在治疗中期,瘤显著减少.
观察到瘤透性淋巴细胞 (TILs) 低于5%,质疑它们目前指导降级的可靠性.

结论:

这一案例支持了在选择的TNBC患者中降级新辅助疗程的潜在可行性.
扩散的炎症反应可能增强了抗瘤免疫力,这需要进一步调查.
经过验证的生物标志物和可靠的成像对于指导降级策略至关重要,以避免妥协结果.

关键词:

美国TNBC电视台为了缓和局势升级.主要注释 52222 这就是为什么.作为一种新辅助治疗,新辅助治疗.在 pCR 中,pCR 值为 pCR.病理学的完整反应.有关副作用的副作用是什么?

更多相关视频

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...